Internal Medicine, Hematology & Oncology · Dublin, GA
NPI
1447447933
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2400 Bellevue Rd, Suite 26 Erin Office Park
Dublin, GA, 31021
Phone (478) 272-8266
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.9M
342,537 services
Medicare patients, 2024
779
Average age 75
Drug cost, 2024
$18.6M
4,716 prescriptions
Company payments, 2025
$2,446
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harsha Vyas was code J1439 (injection, ferric carboxymaltose, 1 mg), 126,750 times for 73 patients. In total Harsha Vyas billed 342,537 services in 141 codes, and Medicare paid $4.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-02-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 126,750 | 73 | $0.87 | $110K |
| J0897 Injection, denosumab, 1 mg | Office | 33,318 | 145 | $20.31 | $677K |
| J0185 Injection, aprepitant, 1 mg | Office | 18,996 | 29 | $1.34 | $25K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 18,019 | 12 | $43.45 | $783K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 12,613 | 27 | $4.39 | $55K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,459 | 43 | $6.25 | $47K |
| J9267 Injection, paclitaxel, 1 mg | Office | 6,993 | 12 | $0.08 | $569 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,825 | 50 | $0.09 | $340 |
| 85025 Blood Count | Office | 3,279 | 732 | $7.57 | $25K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,580 | 20 | $5.83 | $15K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,344 | 25 | $0.07 | $172 |
| 96372 Injection Administration | Office | 1,447 | 222 | $10.16 | $15K |
| 99214 Office E&M - Established | Office | 1,120 | 456 | $90.94 | $102K |
| 96367 Intravenous Infusion, Hydration | Office | 610 | 57 | $20.09 | $12K |
| 96413 Chemotherapy Administration | Office | 523 | 70 | $89.21 | $47K |
By year: 2022 $3.5M for 272,791 services; 2023 $4.6M for 322,669 services; 2024 $4.9M for 342,537 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,279 | 732 | $7.57 | $25K |
| 36415 Venipuncture Blood Collection | 241 | 175 | $8.27 | $1,993 |
Medicare prescription drug claims, 2024
In 2024, the drug Harsha Vyas prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 362 prescriptions and refills. In total Harsha Vyas wrote 4,716 Medicare prescriptions that cost $18.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 362 | 362 | 100 | $1.1M |
| Anastrozole Generic | 344 | 622 | 77 | $5,027 |
| Oxycodone Hcl Generic | 250 | 250 | 62 | $3,245 |
| Prolia Denosumab | 144 | 864 | 88 | $247K |
| Cinvanti Aprepitant | 124 | 124 | 27 | $63K |
| Fentanyl Generic | 117 | 117 | 32 | $12K |
| Xtandi Enzalutamide | 115 | 115 | 17 | $1.6M |
| Neulasta Onpro Pegfilgrastim | 114 | 114 | 29 | $806K |
| Prochlorperazine Maleate Generic | 101 | 101 | 59 | $3,594 |
| Abiraterone Acetate Generic | 94 | 94 | 13 | $264K |
| Sustol Granisetron | 92 | 92 | 23 | $78K |
| Cyproheptadine Hcl Generic | 88 | 106 | 33 | $1,676 |
| Lupron Depot Leuprolide Acetate | 78 | 236 | 27 | $473K |
| Eliquis Apixaban | 77 | 110 | 22 | $70K |
| Xgeva Denosumab | 70 | 70 | 14 | $225K |
Brand drugs: 2,400 claims; generic drugs: 2,316 claims; opioid claims: 485.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harsha Vyas $2,446 ($2,446 in general payments such as food, travel and fees) from 30 companies. The largest payer was ASD Specialty Healthcare, LLC with $415.
| Company | Payments | Amount |
|---|---|---|
| ASD Specialty Healthcare, LLC | 5 | $415 |
| Pfizer Inc. PFE | 21 | $366 |
| Incyte Corporation INCY | 4 | $162 |
| Merck Sharp & Dohme LLC MRK | 7 | $162 |
| Genzyme Corporation SNY | 4 | $126 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $101 |
| Amneal Pharmaceuticals LLC AMRX | 1 | $88.68 |
| Daiichi Sankyo Inc. 4568.T | 3 | $88.2 |
| Seagen Inc. PFE | 1 | $77.99 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $72.39 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.